Total Payments
$374,678
2024 Payments
$55,442
Companies
19
Transactions
288
Medicare Patients
418
Medicare Billing
$87,128
Payment Breakdown by Category
Consulting$157,697 (42.1%)
Other$154,541 (41.2%)
Travel$55,145 (14.7%)
Food & Beverage$7,254 (1.9%)
Education$41.81 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $157,697 | 62 | 42.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $154,541 | 34 | 41.2% |
| Travel and Lodging | $55,145 | 90 | 14.7% |
| Food and Beverage | $7,254 | 97 | 1.9% |
| Education | $41.81 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $133,571 | 104 | $0 (2022) |
| Merck Sharp & Dohme LLC | $72,906 | 43 | $0 (2024) |
| Gilead Sciences, Inc. | $58,096 | 39 | $0 (2024) |
| Daiichi Sankyo Inc. | $22,863 | 18 | $0 (2024) |
| PFIZER INC. | $17,961 | 18 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $12,974 | 20 | $0 (2024) |
| Seagen Inc. | $11,035 | 11 | $0 (2023) |
| GENZYME CORPORATION | $8,563 | 3 | $0 (2022) |
| F. Hoffmann-La Roche AG | $7,596 | 4 | $0 (2018) |
| GE HEALTHCARE | $6,407 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,442 | 35 | Gilead Sciences, Inc. ($18,037) |
| 2023 | $75,023 | 51 | Gilead Sciences, Inc. ($33,042) |
| 2022 | $25,111 | 15 | GENZYME CORPORATION ($8,563) |
| 2021 | $18,220 | 10 | Merck Sharp & Dohme Corporation ($13,260) |
| 2020 | $15,545 | 10 | Seagen Inc. ($6,005) |
| 2019 | $58,791 | 58 | Genentech USA, Inc. ($47,501) |
| 2018 | $80,676 | 64 | Genentech USA, Inc. ($50,372) |
| 2017 | $45,871 | 45 | Genentech USA, Inc. ($35,378) |
All Payment Transactions
288 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | PFIZER INC. | IBRANCE (Drug) | Travel and Lodging | In-kind items and services | $155.51 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $57.69 | General |
| 12/04/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,745.00 | General |
| 11/21/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,125.00 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| Category: Oncology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 10/22/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: ONC | ||||||
| 10/11/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $481.16 | General |
| Category: Oncology | ||||||
| 10/11/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $456.85 | General |
| Category: Oncology | ||||||
| 10/11/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $42.27 | General |
| Category: Oncology | ||||||
| 09/15/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $56.27 | General |
| Category: ONC | ||||||
| 09/14/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $76.24 | General |
| Category: Oncology | ||||||
| 09/13/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $188.41 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 08/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 07/23/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $345.06 | General |
| Category: ONC | ||||||
| 07/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $539.89 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $342.50 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $194.90 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | GE HEALTHCARE | Cerianna (Drug) | Consulting Fee | Cash or cash equivalent | $1,770.00 | General |
| Category: Pharma Imaging Agents - Nuclear Imaging | ||||||
| 07/10/2024 | GE HEALTHCARE | Cerianna (Drug) | Consulting Fee | Cash or cash equivalent | $708.00 | General |
| Category: Pharma Imaging Agents - Nuclear Imaging | ||||||
| 06/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $14,160.00 | General |
| Category: ONC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 76 | 168 | $88,444 | $16,879 |
| 2022 | 6 | 113 | 177 | $84,001 | $16,634 |
| 2021 | 6 | 120 | 255 | $100,244 | $28,636 |
| 2020 | 6 | 109 | 239 | $95,120 | $24,978 |
Total Patients
418
Total Services
839
Medicare Billing
$87,128
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 35 | 73 | $45,912 | $8,281 | 18.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 62 | $26,152 | $6,082 | 23.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 29 | 33 | $16,380 | $2,517 | 15.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 27 | 46 | $29,301 | $5,667 | 19.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 25 | 47 | $19,072 | $3,708 | 19.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 40 | $16,400 | $3,408 | 20.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $9,806 | $1,984 | 20.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 11 | $4,620 | $958.10 | 20.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 20 | 21 | $4,802 | $909.34 | 18.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 38 | 77 | $45,913 | $9,641 | 21.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 12 | 55 | $9,130 | $8,824 | 96.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 30 | 48 | $18,253 | $4,038 | 22.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 46 | $18,109 | $4,004 | 22.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 12 | 13 | $5,236 | $1,189 | 22.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 15 | 16 | $3,603 | $940.80 | 26.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 14 | 56 | $9,296 | $8,898 | 95.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 32 | 83 | $45,576 | $7,144 | 15.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 23 | 57 | $21,003 | $5,126 | 24.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $9,467 | $1,993 | 21.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 14 | 15 | $5,670 | $1,383 | 24.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 13 | 15 | $4,108 | $434.40 | 10.6% |
About Rita Nanda
Rita Nanda is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568524015.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Rita Nanda has received a total of $374,678 in payments from pharmaceutical and medical device companies, with $55,442 received in 2024. These payments were reported across 288 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($157,697).
As a Medicare-enrolled provider, Nanda has provided services to 418 Medicare beneficiaries, totaling 839 services with total Medicare billing of $87,128. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 12/14/2006
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1568524015
Products in Payments
- Trodelvy (Drug) $37,745
- Herceptin (Biological) $27,867
- TUKYSA (Drug) $16,100
- TECENTRIQ (Biological) $13,135
- Enhertu (Drug) $13,033
- Non-Covered Product (Drug) $12,501
- IBRANCE (Drug) $10,011
- Perjeta (Biological) $8,040
- LYNPARZA (Drug) $7,774
- Avastin (Biological) $4,290
- TRODELVY (Drug) $3,850
- VERZENIO (Drug) $2,700
- Cerianna (Drug) $2,557
- Lucitanib (Drug) $1,613
- ENHERTU (Biological) $1,505
- Abraxane (Drug) $1,399
- KEYTRUDA (Biological) $749.04
- Orserdu (Drug) $76.24
- Paclitaxel (Drug) $59.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Randy Sweis
Hematology & Oncology — Payments: $346,946
Hematology & Oncology $346,946